Fragile X Syndrome

Fragile X Syndrome: From Genetics to Targeted Treatment provides a structured overview of the molecular and clinical background of the disorder as well as treatment options. The book discusses the detailed molecular information on each of the pathways involved with sufficient details for all whose research touches this pathway. It provides a state-of-the-art update on all clinical aspects associated with this syndrome, including phenotype, diagnostics and epidemiology.

It also includes an overview of the lessons learned from the preclinical research and pioneering trials on the fragile X syndrome for the investigators involved in clinical trials of neurodevelopmental disorders. This book is written for academic researchers, pharmaceutical investigators, and clinicians in the field who work on the disorder, and for researchers involved in clinical trials of the fragile X syndrome or related disorders.

• Provides a comprehensive overview of the molecular genetics, clinical trials, and treatment of Fragile X Syndrome
• Written for academic researchers, pharmaceutical investigators, and clinicians in the field
• Edited by international leaders in the field who have contributed greatly to the study of Fragile X Syndrome
• Directs the reader through complex issues surrounding FXS and draws the literature together for researchers and clinicians

Researchers and clinical practitioners in neuroscience, neurology, pharmacology, genetics and genetic counseling

Clinics, diagnosis, epidemiology, molecular mechanisms and models
1. The Clinical Phenotype of the Fragile X Syndrome and Related Disorders
2. Fragile X Syndrome Genetics
3. Molecular Diagnostics and Genetic Counseling in Fragile X syndrome and FMR1 associated disorders
4. Epidemiology of Fragile X Syndrome
5. Mechanisms of repeat instability in Fragile X Syndrome
6. Modeling Fragile X Syndrome Using Human Pluripotent Stem Cells
7. Animal models - drosophila, mouse, rat and zebrafish

Pathways Involved
8. RNA and protein targets of FMRP
9. The mGluR Theory of Fragile X
10.  GABA A and B
11. Intracellular signaling networks in Fragile X Syndrome: approaches to drug discovery and therapeutics
12. The endocannabinoid system in Fragile X Syndrome
13. Glycogen synthase kinase-3: Abnormalities and therapeutic potential in Fragile X syndrome
14. Defects in Rho GTPase signaling to the spine actin cytoskeleton in FMR1 knockout mice
15. Matrix Metalloproteinases in Fragile X Syndrome
16. Ion channel dysfunction and FXS
17. Reactivation of FMR1 gene

Clinical trials
18. Drug discovery for targeted pharmacotherapy of Fragile X Syndrome
19. Overview of targeted double blind, placebo controlled clinical trials in Fragile X Syndrome
20. Reflections on Clinical trials in Fragile X syndrome
21. Toward better outcome measures in clinical trials
22. Fragile X Syndrome: From Genetics to Targeted Treatment